After transfection with PTPN3 esiRNAs (esiPTPN3), an endoribonuclease-prepared siRNA pool comprised of a heterogeneous mixture of siRNAs that all target the same mRNA sequence of PTPN3, a significant silencing effect of PTPN3 in both cisplatin and doxorubicin resistant ovarian cancer cells was confirmed by qRT-PCR (Fig. 2A,B). Here, PTPN3 is linked to ovarian carcinoma.